Private Trust Company’s Madrigal Pharmaceuticals MDGL Stock Holding History

Private Trust Company’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61K	Buy	+3	New	+$1.54K	﹤0.01%	2537

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Private Trust Company's MDGL Position: Q2 2026 in Review

Private Trust Company opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 3 shares worth $1.61K. The stake represents ﹤0.01% of the portfolio and ranks #2537 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Private Trust Company held 3 shares of Madrigal Pharmaceuticals worth $1.61K as of Q2 2026.
Madrigal Pharmaceuticals was a new Private Trust Company position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2537 holding.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.